Abstract:Abstract Background Ectopic pregnancy is a major life- and fertility-threatening women’s health concern. As a result of advances in examination technology, an increasing number of ectopic pregnancies can be diagnosed early and treated with medical methods instead of surgery. The aim of this study was to summarize the clinical features and identify the predictors of success of methotrexate (MTX) treatment of ectopic pregnancy. Methods This was a retrospective study of 238 ectopic pregnancies treated with MTX in the Department of Gynecology of Shaanxi Provincial People’s Hospital from January 2017 to December 2017. Results Patients were divided into two groups: the successful treatment group ( n = 166) and the failed treatment group ( n = 72). The overall success rate of MTX therapy for ectopic pregnancy was 69.75%. The mean initial beta-human chorionic gonadotropin (β-hCG) level was significantly lower in the successful treatment group than in the failed treatment group (2538.08 IU/L versus 3533.17 IU/L, P = 0.000). The treatment success rate of the group with an initial β-hCG concentration less than 4000 IU/L was significantly higher than that of the group with an initial β-hCG concentration greater than 4000 IU/L. However, the success rate of the group with an initial β-hCG concentration greater than 4000 IU/L was still relatively high (54.55%). β-hCG levels were significantly increased on the 4th day in the failed treatment group ( P = 0.000). Compared to the initial β-hCG level, the day-4 β-hCG level increased by more than 8.21%, indicating that the treatment was effective. The diagnostic sensitivity was 88.6%, the specificity was 74.5%, and the area under the receiver operating characteristic (ROC) curve was 0.863 (95% confidence interval (CI): 0.805–0.920). Conclusions MTX therapy as a treatment option is safe and effective for asymptomatic, hemodynamically stable patients with ectopic pregnancies who are interested in conservative treatment, regardless of the serum β-hCG level or adnexal mass size. The change in the β-hCG level between the initial day and the 4th day is an effective and early predictive tool for the success of MTX therapy for ectopic pregnancy.

Application Progress of Methotrexate on Ectopic Pregnancy

Methotrexate for the Placenta in Situ in Advanced Abdominal Pregnancy: A Case of Remaining Intra-Abdominal Infection and Myelosuppression after Methotrexate Treatment

Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy

Analysis of risk factors and treatment outcome following methotrexate therapy in ectopic pregnancy

Medical treatment of ectopic pregnancy: a committee opinion

Clinical analysis on ultrasound - guided local injection of methotrexate combined with traditional Chinese medicine in treatment of ectopic pregnancy

Successful Conservative Management with Methotrexate and Mifepristone of Cervical Pregnancy

Single-Dose Methotrexate for Treatment of Ectopic Pregnancy

Clinical study on methotrexate with mifepristone in the treatment of ectopic pregnancy for 60 cases

Methotrexate Management for Placenta Accreta: a Prospective Study

Uterine Artery Embolization in Association with Methotrexate Infusion for the Treatment of Tubal Ectopic Pregnancy

Systemic methotrexate (MTX) in early pregnancy: a retrospective study of a tertiary maternity hospital

[Single Methotrexate Chemotherapy for Low-Risk Gestational Trophoblastic Tumor].

Management of Ectopic Pregnancy by Intramuscular Injection of High Dose of Methotrexate

Therapeutic Effect of Single-dose Methotrexate for Ectopic Pregnancy

Medical management of ectopic pregnancy

To investigate the treatment mode and influence of ectopic pregnancy in gynecology

Clinical Study of the Efficacy Therapy for Persistent Ectopic Pregnancy

The Relation Between Β-Hcg Changing Patterns and Ectopic Pregnancy Drug Therapy Protocol

The Treatment Strategy and Prognosis of the Patients with Ectopic Pregnancy Who Desire Fertility

Treatment of Ectopic Pregnancy by Two Dosages of Mifepristoned Plus Methotrexate